FDA advisory panels: technical input needs rank above COI (conflict of interest) issues
This article was originally published in Clinica
The US FDA must give prior public notice before letting experts with a potential conflict of interest (COI) participate on advisory panels, according to a bill enacted by the US Congress last week.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.